CytomX Therapeutics (NASDAQ:CTMX) Upgraded to “Hold” at Wall Street Zen

Posted by Stanley Muller on Nov 8th, 2026

Wall Street Zen upgraded shares of CytomX Therapeutics (NASDAQ:CTMX – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

A number of other research analysts also recently commented on the company. Zacks Research downgraded CytomX Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. JPMorgan Chase & Co. cut their price target on CytomX Therapeutics from $12.00 to $11.00 and set an “overweight” rating for the company in a research note on Thursday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of CytomX Therapeutics in a report on Tuesday, October 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of CytomX Therapeutics in a report on Friday, September 11th. Finally, Wedbush boosted their price target on CytomX Therapeutics from $11.00 to $12.00 and gave the company an “outperform” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, CytomX Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $12.00.

Get Our Latest Research Report on CTMX

CytomX Therapeutics Stock Up 2.3%

CytomX Therapeutics stock opened at $2.19 on Friday. The company’s fifty day simple moving average is $2.71 and its 200-day simple moving average is $3.81. CytomX Therapeutics has a 12 month low of $2.11 and a 12 month high of $8.21. The stock has a market cap of $477.20 million, a P/E ratio of -4.38 and a beta of 2.23.

CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). CytomX Therapeutics had a negative return on equity of 35.54% and a negative net margin of 608.98%. The company had revenue of $1.69 million during the quarter, compared to analyst estimates of $10.38 million. On average, equities research analysts expect that CytomX Therapeutics will post -0.40 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CytomX Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CTMX. Bank of America Corp DE raised its stake in shares of CytomX Therapeutics by 1,064.3% in the 1st quarter. Bank of America Corp DE now owns 10,202,785 shares of the biotechnology company’s stock valued at $47,953,000 after acquiring an additional 9,326,480 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in CytomX Therapeutics in the 2nd quarter worth approximately $531,000. Wellington Management Group LLP boosted its position in CytomX Therapeutics by 44.3% during the second quarter. Wellington Management Group LLP now owns 5,168,961 shares of the biotechnology company’s stock worth $19,384,000 after purchasing an additional 1,585,976 shares during the period. Stonepine Capital Management LLC bought a new stake in CytomX Therapeutics during the second quarter worth approximately $768,750. Finally, BlackRock Inc. bought a new stake in CytomX Therapeutics during the second quarter worth approximately $65,849,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

More CytomX Therapeutics News

Here are the key news stories impacting CytomX Therapeutics this week:

Positive Sentiment: Wedbush raised its price target to $12 from $11 and maintained an Outperform rating, signaling continued optimism about CytomX’s prospects. Wedbush Raises Price Target
Positive Sentiment: Varseta-M reported 20%–32% objective response rates and a seven-month median progression-free survival in late-line colorectal cancer. The program has FDA Fast Track designation, with pivotal-trial initiation planned for the first half of 2027. The company also had $367 million in cash and potential partnership milestones, although those milestones are contingent on future development and commercial progress. CytomX Stock Trading Near Cash Value
Negative Sentiment: Third-quarter revenue was $1.69 million, well below analyst expectations of $10.38 million. CytomX reported a loss of $0.09 per share; one report characterized this as a $0.02-per-share miss against its consensus estimate. The revenue shortfall and continuing losses may weigh on sentiment. CytomX Q3 Results
Negative Sentiment: The clinical-program outlook carries execution risk, and the cited analysis notes prior dilution and terminated legacy partnerships as concerns that have pressured revenue. CytomX Stock Trading Near Cash Value

CytomX Therapeutics Company Profile

(Get Free Report)

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cancer medicines designed to be activated selectively within the tumor microenvironment. The company’s approach is intended to improve the precision of treatment by limiting activity in healthy tissues while enabling therapeutic effects at tumor sites.

CytomX’s research is based on its Probody therapeutic platform, which uses molecular masking and tumor-associated protease activity to conditionally activate antibody-based medicines.